曲妥珠单抗-美坦新偶联物(T-DM1)在HER2/neu高表达上皮性卵巢癌中体外和体内活性优于曲妥珠单抗、帕妥珠单抗及其联合方案
该临床前研究比较了曲妥珠单抗(T)、帕妥珠单抗(P)、T+P联合及T-DM1对HER2/neu高表达上皮性卵巢癌的抗肿瘤活性,发现40%的原代细胞系为3+高表达,T-DM1在诱导凋亡和体内抑制肿瘤生长方面均优于T+P或单药,作者据此支持设计T-DM1治疗化疗耐药且HER2/neu过表达上皮性卵巢癌的临床研究。
要点
- 40%的原代上皮性卵巢癌细胞系检测到3+ HER2/neu高表达。
- T-DM1诱导的凋亡显著多于T+P(p<0.0001)。
- T-DM1体内抑制肿瘤生长显著优于T、P及T+P(p=0.04)。
核心结论
- 在3+ HER2/neu表达的上皮性卵巢癌体外和体内实验中,T或P单药抗肿瘤活性有限,T-DM1抗肿瘤活性优于T和P单药及T+P联合。
- 作者的临床前数据支持设计T-DM1治疗化疗耐药且HER2/neu过表达上皮性卵巢癌的临床研究。
研究设计与样本
- 研究建立原代上皮性卵巢癌细胞系并分析HER2/neu表达,体外评估T、P、T+P和T-DM1的细胞静止、凋亡和抗体依赖细胞介导的细胞毒作用(ADCC)活性,并在3+ HER2/neu表达的异种移植模型中测试体内抗肿瘤活性。
主要发现
- 40%的原代上皮性卵巢癌细胞系检测到3+ HER2/neu高表达。
- T、P、T+P和T-DM1在诱导针对表达3+ HER2/neu的原代上皮性卵巢癌细胞系的强ADCC方面效果相似。
- T+P联合的细胞静止作用强于T单药(p<0.0001)和P单药(p<0.0001)。
- T-DM1诱导的凋亡显著多于T+P(p<0.0001)。
- 在过表达HER2/neu的上皮性卵巢癌异种移植模型中,T-DM1抑制肿瘤生长的效果显著优于T单药、P单药和T+P(p=0.04)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy. The objective of this study was to compare the anti-tumor activity of HER2/neu-targeting monoclonal antibodies, trastuzumab (T), pertuzumab (P), combination of trastuzumab and pertuzumab (T+P) and trastuzumab-emtansine (T-DM1) in EOC with high HER2/neu expression. METHODS: Primary EOC cell lines were established and cell blocks were analyzed for HER2/neu expression. Cytostatic, apoptotic and antibody-dependent cell-mediated cytotoxicity (ADCC) activities of T, P, T+P and T-DM1 were evaluated in vitro. The in vivo antitumor activity was tested in xenograft models with 3+ HER2/neu expression. RESULTS: High (3+) HER2/neu expression was detected in 40% of the primary EOC cell lines. T, P, T+P, and T-DM1 were similarly effective in inducing strong ADCC against primary EOC cell lines expressing 3+ HER2/neu. The combination of T and P was more cytostatic when compared with that of T or P used alone (p<0.0001 and p<0.0001, respectively). T-DM1 induced significantly more apoptosis when compared with T+P (p<0.0001). Finally, T-DM1 was significantly more effective in tumor growth inhibition in vivo in EOC xenografts overexpressing HER2/neu when compared to T alone, P alone and T+P (p=0.04). CONCLUSION: In vitro and in vivo experiments with 3+ HER2/neu expressing EOC revealed limited anti-tumor activity of T or P. T-DM1 showed superior anti-tumor activity to T and P as single agents and as a combination. Our preclinical data support the design of clinical studies with T-DM1 for the treatment of chemotherapy-resistant EOC overexpressing HER2/neu.
引用
- Menderes G, Bonazzoli E, Bellone S, et al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017. PMID: 28705408. doi:10.1016/j.ygyno.2017.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。